Genelux Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GNLX research report →
Companywww.genelux.com
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer.
- CEO
- Thomas D. Zindrick
- IPO
- 2023
- Employees
- 24
- HQ
- Westlake Village, CA, US
Price Chart
Valuation
- Market Cap
- $108.15M
- P/E
- -2.94
- P/S
- 13518.58
- P/B
- 4.08
- EV/EBITDA
- -3.05
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -3550.00%
- Op Margin
- -422037.50%
- Net Margin
- -397225.00%
- ROE
- -165.18%
- ROIC
- -132.84%
Growth & Income
- Revenue
- $8.00K · 0.00%
- Net Income
- $-32,145,000 · -7.62%
- EPS
- $-0.86 · 9.47%
- Op Income
- $-33,214,000
- FCF YoY
- -22.01%
Performance & Tape
- 52W High
- $8.54
- 52W Low
- $2.29
- 50D MA
- $2.67
- 200D MA
- $3.78
- Beta
- 0.50
- Avg Volume
- 194.56K
Get TickerSpark's AI analysis on GNLX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Yu Yong | sell | 605 |
| May 11, 26 | Cappello Joseph | sell | 605 |
| May 11, 26 | Zindrick Thomas | sell | 2,798 |
| May 11, 26 | Smalling Ralph | sell | 270 |
| Mar 24, 26 | Smalling Ralph | sell | 345 |
| Mar 25, 26 | Smalling Ralph | sell | 240 |
| Mar 24, 26 | Cappello Joseph | sell | 906 |
| Mar 24, 26 | Yu Yong | sell | 906 |
| Mar 24, 26 | Zindrick Thomas | sell | 3,582 |
| Mar 2, 26 | Thomas John | sell | 10,000 |
Our GNLX Coverage
We haven't published any research on GNLX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GNLX Report →